New eye drop shows promise for rare corneal disease
NCT ID NCT04485546
First seen Nov 10, 2025 · Last updated May 09, 2026 · Updated 30 times
Summary
This study tested an eye drop called OXERVATE in 37 adults with stage 1 neurotrophic keratitis, a condition where the cornea loses feeling and doesn't heal properly. The treatment was given for 8 weeks, and patients were followed for 24 weeks to see if the cornea healed safely. The goal was to check how well the drops work and if they are safe for this early stage of the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROTROPHIC KERATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston
Boston, Massachusetts, 02111, United States
-
Edgewood
Edgewood, Kentucky, 41017, United States
-
Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Saint Louis
St Louis, Missouri, 63131, United States
-
San Diego
San Diego, California, 92122, United States
Conditions
Explore the condition pages connected to this study.